VIR

10.28

3.38% -0.36

Dopo l'orario di chiusura: 10.27 -0.010 -0.10%

Vir Biotechnology Inc (VIR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché VIR Giù? Forum Previsione

Precedente Chiudi:

$10.64

Aprire:

$10.71

Volume 24 ore:

1.65M

Relative Volume:

0.51

Capitalizzazione di mercato:

$1.66B

Reddito:

$68.56M

Utile/perdita netta:

$-437.99M

Rapporto P/E:

-3.2492

EPS:

-3.1639

Flusso di cassa netto:

$-396.61M

1 W Prestazione:

-5.08%

1M Prestazione:

+22.38%

6M Prestazione:

+59.88%

1 anno Prestazione:

+68.52%

Intervallo 1D:

$10.17

$10.90

Intervallo di 1 settimana:

$10.00

$10.96

Portata 52W:

$4.155

$11.66

Vir Biotechnology Inc Stock (VIR) Company Profile

Nome

Vir Biotechnology Inc

Settore

Healthcare (1107)

Industria

Biotechnology (620)

Telefono

415-906-4324

Indirizzo

1800 OWENS STREET, SAN FRANCISCO, CA

Dipendente

367

Cinguettio

@Vir_Biotech

Prossima data di guadagno

2026-05-06

Ultimi documenti SEC

VIR's Discussions on Twitter

Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VIR Vir Biotechnology Inc	10.28	1.72B	68.56M	-437.99M	-396.61M	-3.1639
VRTX Vertex Pharmaceuticals Inc	430.14	108.36B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	731.77	78.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	775.03	48.74B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	302.11	41.16B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	298.16	33.17B	5.36B	287.73M	924.18M	2.5229

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-24	Aggiornamento	Raymond James	Outperform → Strong Buy
2025-09-03	Iniziato	Evercore ISI	Outperform
2025-08-27	Aggiornamento	BofA Securities	Neutral → Buy
2024-01-29	Downgrade	JP Morgan	Overweight → Neutral
2023-09-08	Downgrade	BofA Securities	Buy → Neutral
2023-03-06	Aggiornamento	JP Morgan	Neutral → Overweight
2023-02-21	Aggiornamento	Goldman	Neutral → Buy
2023-01-27	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2022-09-14	Iniziato	SVB Leerink	Outperform
2022-09-09	Iniziato	Morgan Stanley	Underweight
2022-03-03	Aggiornamento	Robert W. Baird	Underperform → Neutral
2021-12-21	Downgrade	Robert W. Baird	Neutral → Underperform
2021-10-25	Aggiornamento	JP Morgan	Underweight → Neutral
2021-09-22	Downgrade	Goldman	Buy → Neutral
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-01-27	Downgrade	JP Morgan	Neutral → Underweight
2021-01-20	Reiterato	H.C. Wainwright	Buy
2020-10-05	Iniziato	BofA Securities	Buy
2020-09-14	Aggiornamento	Goldman	Neutral → Buy
2020-09-11	Aggiornamento	JP Morgan	Underweight → Neutral
2020-08-20	Iniziato	Needham	Buy
2020-03-19	Downgrade	JP Morgan	Neutral → Underweight
2020-03-13	Downgrade	Goldman	Buy → Neutral
2020-02-27	Downgrade	Robert W. Baird	Neutral → Underperform
2020-02-04	Downgrade	JP Morgan	Overweight → Neutral
2019-11-14	Iniziato	Robert W. Baird	Neutral
2019-11-05	Iniziato	Barclays	Overweight
2019-11-05	Iniziato	Cowen	Outperform
2019-11-05	Iniziato	Goldman	Buy
2019-11-05	Iniziato	JP Morgan	Overweight

Mostra tutto

Vir Biotechnology Inc Borsa (VIR) Ultime notizie

08:15 AM

Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18 - Moomoo

08:15 AM

03:11 AM

Certain Stock options of Vir Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com

Apr 26, 2026

Is VIR a Good Stock to Buy? - HarianBasis.co

Apr 26, 2026

Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Insider Monkey

Apr 26, 2026

Apr 24, 2026

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - BioSpace

Apr 24, 2026

Apr 23, 2026

Press Release: Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - 富途牛牛

Apr 23, 2026

Vir Biotechnology to release Q1 2026 earnings on May 6 ahead of investor call - Traders Union

Apr 23, 2026

Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update - TipRanks

Apr 23, 2026

Apr 22, 2026

Vir Biotechnology Expands Oncology Pipeline via Astellas Partnership - HarianBasis.co

Apr 22, 2026

Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth - Insider Monkey

Apr 22, 2026

Apr 21, 2026

VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Apr 21, 2026

Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows - simplywall.st

Apr 21, 2026

Vir Biotechnology Doses First Patient in Prostate Cancer Clinical Trial - HarianBasis.co

Apr 21, 2026

Apr 20, 2026

Vir Biotechnology stock hits 52-week high at $10.94 By Investing.com - Investing.com Australia

Apr 20, 2026

Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year HighHere's Why - MarketBeat

Apr 20, 2026

Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer? - insidermonkey.com

Apr 20, 2026

Vir Biotechnology stock hits 52-week high at $10.94 - Investing.com

Apr 20, 2026

Apr 19, 2026

Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In? - Insider Monkey

Apr 19, 2026

Apr 18, 2026

8 Best Low Priced Biotech Stocks to Invest In - Insider Monkey

Apr 18, 2026

Apr 16, 2026